Anixa Biosciences Participant In Its Current Phase 1 Study Of FSHR-Targeted CAR-T Therapy For Recurrant Ovarian Cancer Demonstrates Stable Disease After 90 Days Of Treatment; Patient Was Treated In Fifth Dose Cohort

Anixa Biosciences, Inc. (NASDAQ: ANIX) reported that a patient in its Phase 1 clinical trial for FSHR-targeted CAR-T therapy for recurrent ovarian cancer showed stable disease after 90 days of treatment. This marks the first positive response in the trial, with the patient receiving the highest dose level of 1×10⁷ CAR-positive cells per kilogram. No dose-limiting toxicities have been observed in the study thus far, and correlative studies on CAR positive cells are ongoing.